Bristol-Myers says trial of small cell lung cancer treatment failed to meet main goal
Bristol-Myers Squibb Co. said Friday a late-stage trial of a treatment for small cell lung cancer failed to meet its main goal. The drug company said the Phase 3 study called CheckMate-331 evaluating its opdivo in patients with the disease who relapsed following platinum-based chemotherapy failed to meet its primary endpoint of overall survival. “Small cell lung cancer is a highly aggressive disease in which significant unmet need remains,” said Sabine Maier, development lead, thoracic cancers, at Bristol-Myers Squibb. “We are focused on researching innovative oncology therapies to improve outcomes for patients with lung cancer.” Shares were slightly higher premarket, but have fallen 6.1% in 2018, while the S&P 500 has gained 2.1%.